This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1

This study has been completed.
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: February 19, 2004
Last updated: January 11, 2017
Last verified: April 2010
The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.

Condition Intervention Phase
Opioid-Related Disorders Drug: Buprenorphine Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Opiate abstinence

Estimated Enrollment: 516
Study Start Date: June 2003
Study Completion Date: May 2005
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   15 Years to 99 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females are not pregnant or lactating
  • Subjects meet DSM-IV criteria for opiate dependence, are medically and psychiatrically stable, and do not have a current history of benzodiazepine dependence abuse, dependence, or treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00078117

United States, Colorado
Addiction Research & Treatment Services (ARTS)
Denver, Colorado, United States, 80204
Denver Health & Hospitals Authority
Denver, Colorado, United States, 80204
United States, Connecticut
Hartford Dispensary
Hartford, Connecticut, United States, 06120
Connecticut Counseling Centers
Waterbury, Connecticut, United States, 06705
United States, New York
LI Jewish Health System
Glen Oaks, New York, United States, 11004
New York VA Medical Center
New York, New York, United States, 10010
United States, North Carolina
South Light-Wakeview Clinic
Raleigh, North Carolina, United States, 27610
Coastal Horizons Center, Inc.
Wilmington, North Carolina, United States, 28412
United States, Oregon
Portland, Oregon, United States, 97214
United States, Virginia
Norfolk CSB
Norfolk, Virginia, United States, 23505
United States, Washington
Providence Behavioral Health Services
Everett, Washington, United States, 98201
Sponsors and Collaborators
University of California, Los Angeles
Principal Investigator: Walter Ling, M.D. University of California, Los Angeles
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Walter Ling, M.D., University of California, Los Angeles Identifier: NCT00078117     History of Changes
Other Study ID Numbers: NIDA-CTN-0003-1
Study First Received: February 19, 2004
Last Updated: January 11, 2017

Keywords provided by National Institute on Drug Abuse (NIDA):
opiate dependence

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine, Naloxone Drug Combination
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists processed this record on August 18, 2017